Ajanta Pharma conferred as "Best Managed Companies" in India by Deloitte

Published On 2022-10-18 09:00 GMT   |   Update On 2022-10-18 09:00 GMT

Mumbai: Ajanta Pharma, a specialty pharmaceutical formulation company, has been awarded as "Best Managed Companies" in India by Deloitte for 2022. The selection process for the award had rigorous evaluation of management abilities for Strategy; Capabilities and Innovation; Governance and Financials; Culture and Commitment. Mr. Yogesh Agrawal, Managing Director, Ajanta Pharma received...

Login or Register to read the full article

Mumbai: Ajanta Pharma, a specialty pharmaceutical formulation company, has been awarded as "Best Managed Companies" in India by Deloitte for 2022. The selection process for the award had rigorous evaluation of management abilities for Strategy; Capabilities and Innovation; Governance and Financials; Culture and Commitment.

Mr. Yogesh Agrawal, Managing Director, Ajanta Pharma received the award at the Best Managed Companies programme held on 14 October at Deloitte Knowledge Center in Mumbai.

Read also: NPPA panel fixes MRP of Ajanta Pharma Metoprolol Tartrate, lvabradine Hydrochloride FDC

"We are delighted to receive the Best Managed Companies award from Deloitte as it validates our emphasis on commitment towards excellence in people, processes, infrastructure and practices. This award is dedicated to over 7,000 motivated Ajantaites spread globally who make Ajanta an exciting and vibrant place to work." said Mr. Yogesh Agrawal.

Read also: Ajanta Pharma launches generic asthma drug in US market

Ajanta Pharma is a specialty pharmaceutical formulation company having branded generic business in India and 30 emerging markets, a generic business in the US, and an institution business in Africa. The company has 6 world-class formulations & 1 API manufacturing facility in India. Stringent authorities like the USFDA and WHO have approved the company's facilities at Paithan in Maharashtra and Dahej in Gujarat.

For the last 10 financial years, the company has posted healthy performance with its Revenue from Operations growing at 15% CAGR and net profit at 23% CAGR. 

Read also: Ajanta Pharma board nod to Rs 286-crore share buyback plan

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News